{"id":"azd0171","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Pneumonia"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K delta subunit, AZD0171 is thought to modulate the immune response and potentially treat various diseases.","oneSentence":"AZD0171 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:25.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT04999969","phase":"PHASE2","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-12-10","conditions":"Locally Advanced or Metastatic Solid Tumours","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MSC-1"],"phase":"phase_2","status":"active","brandName":"AZD0171","genericName":"AZD0171","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD0171 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}